Senseonics Holdings Inc (NASDAQ:SENS)‘s stock had its “buy” rating restated by equities research analysts at Canaccord Genuity in a research report issued to clients and investors on Wednesday.

The analysts wrote, “We maintain our BUY rating following Q3/17 results that demonstrated continued strong commercial momentum of Eversense in Europe. Q3/17 revenues of $2.1M were well ahead of our Street-high estimate of $1.7M and consensus of $1.5M. As anticipated, Senseonics benefited from a meaningful acceleration in OUS sales as Senseonics continued to execute in its core markets (Germany, Italy, Sweden), had 4 additional countries transition from pilot to full commercial launch, and added an additional 6 geographies. Offsetting strong OUS execution was the announcement that the timelines for US regulatory approval have slipped and the company now expects a PMA panel in the Q1/18, which likely delays US market entry to mid-2018.””

Separately, Zacks Investment Research lowered shares of Senseonics Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th.

Senseonics Holdings (NASDAQ:SENS) last announced its quarterly earnings data on Tuesday, October 31st. The company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The company had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $1.51 million. The company’s quarterly revenue was up 425.0% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at

In other news, COO Mukul Jain sold 11,885 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $3.25, for a total transaction of $38,626.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

A number of institutional investors and hedge funds have recently bought and sold shares of SENS. Renaissance Technologies LLC acquired a new stake in Senseonics Holdings during the 1st quarter worth approximately $111,000. Susquehanna International Group LLP acquired a new stake in Senseonics Holdings during the 2nd quarter worth approximately $155,000. LMR Partners LLP acquired a new stake in Senseonics Holdings during the 2nd quarter worth approximately $177,000. Goldman Sachs Group Inc. acquired a new stake in Senseonics Holdings during the 2nd quarter worth approximately $276,000. Finally, ING Groep NV increased its position in Senseonics Holdings by 87.7% during the 2nd quarter. ING Groep NV now owns 225,833 shares of the company’s stock worth $406,000 after purchasing an additional 105,494 shares in the last quarter.

About Senseonics Holdings

Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.

Receive News & Ratings for Senseonics Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.